2 completed, 1 terminated, 1 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 1, Withdrawn 1 |
Follow Tigris Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AFP464 +/- Faslodex in ER + Breast Cancer AFP464, AFP464 + Faslodex - Breast Neoplasm | Phase 2 | Terminated | Tigris Pharmaceuticals | 7 | 2011-05-01 | 2012-01-09 |
| Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer Aminoflavone Prodrug - Breast Neoplasm | Phase 2 | Withdrawn | Tigris Pharmaceuticals | 50 | 2010-04-01 | 2010-11-03 |
| A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL) A-007 - Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia | Phase 2 | Completed | Tigris Pharmaceuticals | 11 | 2007-11-01 | 2009-05-22 |
| Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix placebo, A007 - Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia | Phase 2 | Completed | Tigris Pharmaceuticals | 147 | 2006-01-01 | 2010-10-11 |
Breast Neoplasms (2) · Squamous Intraepithelial Lesions (2) · Uterine Cervical Dysplasia (2)
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (2) · Fulvestrant (1) · aminoflavone (1)
United States (3)
Cynthia J Goldberg, MD (2) · Keith A Aqua, MD (2) · Mark H Einstein, MD (2) · Robert Pfeffer, MD (2) · Allan T Sawyer, MD (1) · Ana Eduardo, MD (1) · Daron G. Ferris, MD (1) · Douglas G Young, MD (1) · G. Michael Swor, MD (1) · Garn R Mabey, MD (1) · Giuseppe Del Priore, MD (1) · James A Williams, MD (1) · Joanne L. Blume, M.D. (1) · John A Burigo, MD (1) · Jonathan A Cosin, MD (1)